Market Outlook The U.S. treatment landscape for osteoarthritic (OA) pain, despite being highly genericized, contains a large number of brand-only agents, including multiple opioid analgesics with…
The Orphan Drug Act of 1983 encourages the development of drugs for rare diseases, a process with unique clinical and commercial challenges. Although manufacturers of orphan drugs generally enjoy…
Market Outlook The migraine prophylaxis market stands poised for disruption with the launch of Amgen/Novartis’s Aimovig (erenumab) in May 2018 and three additional anti-CGRP monoclonal…
Market Outlook The migraine prophylaxis market stands poised for disruption with the launch of Amgen/Novartis’s Aimovig (erenumab) in May 2018 and three additional anti-CGRP monoclonal…
MARKET OUTLOOK The introduction of additional Crohn’s disease (CD) agents has shifted—and will continue to shift—market dynamics. The newer non-TNF biologics (Takeda’s Entyvio and Janssen…
MARKET OUTLOOK The introduction of additional Crohn’s disease (CD) agents has shifted—and will continue to shift—market dynamics. The newer non-TNF biologics (Takeda’s Entyvio and Janssen…
The increasing rates of resistance to antibiotics among gram-negative pathogens have driven the development of antibiotics that target specific mechanisms of resistance and/or bacterial species…
MARKET OUTLOOK The increasing rates of resistance to antibiotics among gram-negative pathogens have driven the development of antibiotics that target specific mechanisms of resistance and/or…
Market Outlook Despite the broad availability of antidepressants and atypical antipsychotics approved to treat major depressive disorder (MDD), approximately one-third of these patients are…
With the availability of multiple approved products for the treatment of diabetic macular edema (DME) in the EU5, including Bayer HealthCare’s Eylea, Novartis’s Lucentis, Allergan’s Ozurdex,…
With the availability of multiple approved products for the treatment of diabetic macular edema (DME) in the EU5, including Bayer HealthCare’s Eylea, Novartis’s Lucentis, Allergan’s Ozurdex,…
MARKET OUTLOOK Progress in R&D and technology, regulatory and monetary incentives for advancing the development of treatments for rare diseases, and ongoing focus by the pharmaceutical market on…
Truxima (rituximab), Celltrion’s MabThera biosimilar, became the first oncology monoclonal antibody biosimilar to enter the European market in April 2017. Two months later, Sandoz’s Rixathon, a…
Truxima (rituximab), Celltrion’s MabThera biosimilar, became the first oncology monoclonal antibody biosimilar to enter the European market in April 2017. Two months later, Sandoz’s Rixathon, a…
Celltrion’s Herzuma (trastuzumab) is the first biosimilar of Roche’s blockbuster HER2-targeted therapy, Herceptin, to launch in Europe. This series tracks uptake of Herzuma and medical…